Drug Trial Radar · NCT07205159
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Oct 23, 2025
Primary completion
Mar 10, 2027
Study completion Mar 10, 2027
Sponsor
- Lead sponsor
- Forte Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
Conditions
- Alopecia Areata
Interventions
FB102Drug
Route of administration- Intravenous (IV)
PlaceboDrug
Route of administration- Intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Upto 36 Weeks post first dose administration
- Change from Baseline of Severity of Alopecia Tool (SALT) score at Week 16.Time frame: From Screening through Week 16.
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
St Leonards
Saint Leonards, New South Wales (nsw), Australia · Not yet recruiting
Coorparoo
Coorparoo, Queensland, Australia · Recruiting
South Yarra
South Yarra, Victoria, Australia · Not yet recruiting
Auckland
Auckland, Auckland, New Zealand · Not yet recruiting
Christchurch
Christchurch, Canterbury, New Zealand · Not yet recruiting
Palmerston North
Palmerston North, Palmerston North Central, New Zealand · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.